Morgan Stanley analyst Terence Flynn initiates coverage on United Therapeutics (NASDAQ:UTHR) with a Overweight rating and announces Price Target of $288.
Morgan Stanley analyst Terence Flynn initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Underweight rating and announces Price Target of $37.